Special ReportsAll NewsFDA BriefsOncology IconsThe Targeted PulseVoices from the Field
Conference CoverageConference ListingData Dialogue with the Oncology Brothers
All VideosCase-Based Peer PerspectivesEvolving Paradigms in OncologyExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPersonalized MedicinePivotal Practice Views with the Oncology BrothersPodcastsSpeaking Out
All PublicationsEvolving ParadigmsPeers & Perspectives in OncologyTargeted Therapies in Oncology
CASE-BASED ROUNDTABLEPARTNERS
CME/CEClinical TrialsEventsPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
SUBSCRIBE
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Myeloma
  • Chronic Lymphocytic Leukemia
  • Gynecologic Cancers
  • Genomic Testing
  • Melanoma
  • Genitourinary Cancers
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CASE-BASED ROUNDTABLE
    • PARTNERS
    • SUBSCRIBE

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Research Explores Possible Link Between Gut Microbiome and Better Outcomes in Kidney Cancer

February 3, 2022
By Jordyn Sava
Article

In Partnership With

In an interview with Targeted Oncology, Nazli Dizman, MD, discussed the role of gut microbiome in cancer and speaks to her presentation given at IKCS.

Nazli Dizman, MD

Nazli Dizman, MD

Gut microbiome diversities play a large role in modulating response to immunotherapy in patients with cancer, according to Nazli Dizman, MD, who gave presentation on the topic during the 2021 International Kidney Cancer Symposium (IKCS).

Microbial diversity is associated with better treatment outcomes characterized by changes in microbial species over the course of treatment, Dizman, an Internal Medicine residentat Yale Department of Internal Medicine explained during her presentation. This impacts the immune system either positively or negatively through one’s diet, probiotics, antibiotics and cancer treatments with evidence consistent across studies regardless of cancer type, therapeutic setting, cohort size and geography.

Future studies aim to look at the discrepancies that exist between clinically relevant species reported throughout different studies. By delving deep into different species and their biologic functions and assessing gut microbiome functionality will help us understand the connection between microbial communities and their outcomes.

In an interview with Targeted OncologyTM, Dizman, discussed the role of gut microbiome in cancer and speaks to her presentation given at IKCS.

Targeted Oncology: Can provide a brief overview of your IKCS presentation around the role of the microbiome in cancer?

Dizman: There are trillions of bacteria that reside in our body and when you look at a man with 75 kilograms, they would have approximately 200 grams of bacteria in their body. So, microbiome is very important in many diseases, including cancers. There have been so many advancements in microbiome research recently, and we have a lot of data now linking outcomes with microbiome characteristics. This can include gut microbiome diversity, which has been consistently shown to be associated with better clinical outcomes in different cancer types, different cancer settings, different treatment settings, different cohorts, and different countries.

Gut microbiome diversities are playing an important role in modulating one's response to immunotherapy as a diverse microbiome is a better microbiome. There are also a few other species that were shown to be associated with response immunotherapies and targeted therapies too such as akkermansia muciniphila which has shown to be associated with better outcomes with immunotherapies in several cancer types, including renal cell carcinoma. Bacterial species are associated with worse outcomes when they are abundant in one school. Overall, there's still inconsistencies across different studies in terms of the association between certain species and the outcomes, but what is consistent across studies is the microbiome diversity. In my presentation, I also mentioned that antibiotics may have detrimental roles in a patient's response to immunotherapies again, and even with targeted therapies, we have some evidence showing their role as a determinant of response. It doesn't mean that we should refrain from antibiotics, but we should be using them very mindfully. Beyond that, now we have techniques to modulate gut microbiome.

Fecal microbiome transplantation has made an amazing success in small sample size studies. Investigators overcame immunotherapy resistance, investigators treated immune related colitis, with fecal microbiota transplant in patients with different types of cancers, and in addition to that, we recently presented results from a pilot randomized study in renal cell carcinoma patients. We randomized them into two groups where one group received a live bacterial product, and they demonstrated better clinical outcomes including better progression free survival and higher rates of response. So, there's a lot of exciting advancements happening in microbiome research. There's still a lot to learn and there's still a lot to do, but it's very exciting and I'll be mentioning the details or those points in my presentation at IKCS.

What role specifically does the microbiome play in cancers like renal cell carcinoma?

In general gut microbiome affects the immune system in different ways, including its metabolites going to circulation, stemming circulation, changing immune responses, with the presence of bacteria in tumor microenvironment and this way modulating immune-risk cancers. In renal cell carcinoma, we have a lot of data that has been done in the United States and in Europe in large cohorts looking at response characteristics and it looks like its determinant of better outcomes in renal cell carcinoma as well, beyond that microbial diversity which is so important. This has been shown in renal cell carcinoma to be associated with better outcomes with immunotherapy patients.

Also, our study that I mentioned where we attempted to modulate gut microbiome with live bacterial production obtained very interesting, impressive results in patients treated with this live bacterial product. In renal cell carcinoma where we have immunotherapies as the backbone of treatment, microbiome is going to play an important role and is playing an important role, and we investigators need to work a little bit more to understand how we can modulate and how we can use microbiome to help treat cancer.

What should community oncologists know about the microbiome when they're treating their patients?

When we treat our patients, mindful use of antibiotics is a key point. At this point, we have a very big reliable meta-analysis showing the mental effects of antibiotics on response to immunotherapies. I assume that community oncologists are probably getting questions about provider cues and even the use of live bacterial production given those impressive results that we obtained. So as an answer to those questions, we have limited data obtained from a small study, despite that it is very impressive. We are currently working on gut microbiome and trying to understand how we can modulate gut microbiome and perhaps get better outcomes in larger data sets. I think one thing to know is that research is still evolving, and there are a lot of unknown unknowns as well. Keeping track of what's happening in the field would be a recommendation from me to them as they might get questions from the patients about modulation. And if they have a close by center with clinical trials that evaluate gut microbiome or its modulation, referring interested patients into those places might be a recommendation as well.

What do you want oncologists to take away from your talk?

I think the key takeaway from my presentation is that gut microbiome diversity is probably the main thing that is causing the relationship between these outcomes and microbial characteristics. Beyond that, there are a few species that are shown to be associated with outcomes, but there are still a lot of discrepancies. In future studies, we'll work on assessing gut microbiome functionality, which can help us understand whether microbial communities cooperate and change the outcomes or modulate outcomes or different microbial species might have overlapping functional profiles and this might be the determinant of the outcomes.

REFERENCE:

Dizman N. Role of the microbiome in Cancer. Presented at the International Kidney Cancer Symposium: North America. November 5-6, 2021; Austin, TX

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
1 expert in this video
1 expert in this video
1 expert in this video
1 expert in this video
Related Content

George Shares Takeaways From IO Trials and AE Management in Pretreated RCC

George Shares Takeaways From IO Trials and AE Management in Pretreated RCC

Targeted Oncology Staff
June 18th 2025
Article

During a live event, Saby George, MD, and participants discussed tolerability concerns in patients with recurrent renal cell carcinoma who received prior immune checkpoint inhibitor.

Read More


Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC

Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC

Jordyn Sava;Peter Zang, MD
March 1st 2024
Podcast

In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.

Listen


Zanzalintinib/Nivolumab Combo Shows Promise in Advanced RCC

Zanzalintinib/Nivolumab Combo Shows Promise in Advanced RCC

Benjamin Saylor
June 14th 2025
Article

The STELLAR-002 study reports promising efficacy and manageable safety for zanzalintinib plus nivolumab in untreated stage 4 RCC patients.

Read More


Beyond the First-Line: Economides on Advancing Therapies in RCC

Beyond the First-Line: Economides on Advancing Therapies in RCC

Jordyn Sava;Minas P. Economides, MD
February 1st 2024
Podcast

In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.

Listen


Cytoreductive Nephrectomy in the Era of Immunotherapy for Kidney Cancer

Cytoreductive Nephrectomy in the Era of Immunotherapy for Kidney Cancer

Jordyn Sava
June 12th 2025
Article

Hyung Kim, MD, discussed the PROBE trial, a trial in progress, for patients with advanced kidney cancer.

Read More


Pembrolizumab Extends Survival in RCC: 5-Year Study Results

Pembrolizumab Extends Survival in RCC: 5-Year Study Results

Silas Inman
June 12th 2025
Article

Pembrolizumab consistently improves overall and disease-free survival in clear cell renal cell carcinoma, showing sustained benefit at 5 years post surgery.

Read More

Related Content

George Shares Takeaways From IO Trials and AE Management in Pretreated RCC

George Shares Takeaways From IO Trials and AE Management in Pretreated RCC

Targeted Oncology Staff
June 18th 2025
Article

During a live event, Saby George, MD, and participants discussed tolerability concerns in patients with recurrent renal cell carcinoma who received prior immune checkpoint inhibitor.

Read More


Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC

Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC

Jordyn Sava;Peter Zang, MD
March 1st 2024
Podcast

In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.

Listen


Zanzalintinib/Nivolumab Combo Shows Promise in Advanced RCC

Zanzalintinib/Nivolumab Combo Shows Promise in Advanced RCC

Benjamin Saylor
June 14th 2025
Article

The STELLAR-002 study reports promising efficacy and manageable safety for zanzalintinib plus nivolumab in untreated stage 4 RCC patients.

Read More


Beyond the First-Line: Economides on Advancing Therapies in RCC

Beyond the First-Line: Economides on Advancing Therapies in RCC

Jordyn Sava;Minas P. Economides, MD
February 1st 2024
Podcast

In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.

Listen


Cytoreductive Nephrectomy in the Era of Immunotherapy for Kidney Cancer

Cytoreductive Nephrectomy in the Era of Immunotherapy for Kidney Cancer

Jordyn Sava
June 12th 2025
Article

Hyung Kim, MD, discussed the PROBE trial, a trial in progress, for patients with advanced kidney cancer.

Read More


Pembrolizumab Extends Survival in RCC: 5-Year Study Results

Pembrolizumab Extends Survival in RCC: 5-Year Study Results

Silas Inman
June 12th 2025
Article

Pembrolizumab consistently improves overall and disease-free survival in clear cell renal cell carcinoma, showing sustained benefit at 5 years post surgery.

Read More

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Editorial Board
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.